Literature DB >> 4617706

Facilitation and inhibition of b16 melanoma by BCG in vivo and by lymphoid cells from bcg-treated mice in vitro.

D O Chee, A J Bodurtha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4617706     DOI： 10.1002/ijc.2910140117

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  5 in total

Review 1.  Cell walls of Mycobacteria and related organisms; chemistry and immunostimulant properties.

Authors:  E Lederer; A Adam; R Ciorbaru; J F Petit; J Wietzerbin
Journal:  Mol Cell Biochem       Date:  1975-05-30       Impact factor: 3.396

2.  The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. I: The local nature of immunostimulation and the effects of delayed-type hypersensitivity.

Authors:  W R Roche; H McLaughlin
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

3.  Mycobacterium bovis, BCG, modulation of murine antibody responses: influence of dose and degree of aggregation of live or dead organisms.

Authors:  C A Brown; I N Brown
Journal:  Br J Exp Pathol       Date:  1982-04

4.  Inhibition of pulmonary metastases of B16 melanoma with irradiated tumor cells and BCG.

Authors:  J Tai; A Guclu; T Ghose; S Norvell
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors?

Authors:  E B Bröcker; L Suter; B M Czarnetzki; E Macher
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.